The application value of rifapentine blood concentration monitoring in the intervention treatment of latent tuberculosis in children

doi:10.19871/j.cnki.xfcrbzz.2026.02.001

Abstract

Abstract: Objective To evaluate the safety and clinical efficacy of blood concentration monitoring of rifapentine in the intervention treatment of latent tuberculosis infection in children, in order to ensure medication safety and reduce adverse reactions of children's medication. Method A total of 110 children with latent tuberculosis infection who received preventive interventional treatment at Shenzhen Third People's Hospital between January 2023 and December 2024 were enrolled, and their rifapentine plasma concentrations were detected and analyzed by two-dimensional high-performance liquid chromatography. Plasma drug concentrations at 1h, 2h, 4h, and 6h under steady-state conditions were collected. Combined with the dosage regimen, demographic characteristics (age, gender, weight) and laboratory test results, the plasma drug concentration after 2h of medication was investigated, and its correlation with gender, age, weight and other factors in tolerance risk was discussed. Result The proportions of subjects whose rifapentine concentrations fell within the therapeutic window (8-30 μg/ml) at 1h, 2h, 4h, and 6h were 71.81%, 88.18%, 81.81%, and 73.63%, respectively, and the plasma drug concentrations at all time points were mainly within the therapeutic window. The proportion of 2h drug concentration in the treatment window was significantly higher than that of the other three, and the difference was statistically significant (χ²=13.74, P<0.001; χ²=4.29, P<0.05; χ²=11.72, P<0.001). Further analysis showed that among the influencing factors leading to 2h plasma drug concentration below the therapeutic range, the concentration in males was slightly lower than that in females, but the difference was not statistically significant (χ²=0.002, P>0.05). The difference between age group (χ²=4.130, P<0.05) and weight group (χ²=4.472, P<0.05) was statistically significant. Conclusion Through therapeutic drug monitoring of rifapentine in children with latent tuberculosis infection, the plasma drug concentration of most children reaches the therapeutic window at 2h after administration, and no increase in the incidence of adverse reactions or abnormalities in laboratory indicators is observed. This method is conducive to achieving precise drug administration and individualized treatment, thereby improving clinical efficacy and medication safety.

Key words: Latent tuberculosis infection, Two-dimensional liquid chromatography, Rifapentine, Drug monitoring, Pharmacokinetics

CLC Number:

R521
R529.9

Zhang Yaxi, Li Jing, Yang Qianting, Wang Min, Chen Qi. The application value of rifapentine blood concentration monitoring in the intervention treatment of latent tuberculosis in children[J]. Electronic Journal of Emerging Infectious Diseases, 2026, 11(2): 1-5.

References

[1] 李媛媛, 谢晶晶, 李树涛, 等. 2024年WHO全球结核病报告:全球与中国关键数据分析[J/CD]. 新发传染病电子杂志, 2024, 9(6):92-98.
[2] COLEMAN M, NGUYEN TA, LUU BK, et al.Finding and treating both tuberculosis disease and latent infection during population-wide active case finding for tuberculosis elimination[J]. Front Med (Lausanne) , 2023, 10:1275140.
[3] 王丽莎, 李娜, 闫晓婷, 等. 潜伏性结核感染预防性治疗中的医学困境及解决策略[J]. 医学与哲学, 2024, 45(18):68-72.
[4] JAIN SK, ANDRONIKOU S, GOUSSARD P, et al.Advanced imaging tools for childhood tuberculosis: potential applications and research needs[J]. Lancet Infect Dis, 2020, 20(11): e289-e297.
[5] STARKE JR, CRUZ AT.et al.The global nature of childhood tuberculosis[J]. Pediatrics, 2014, 133(3): e725-e727.
[6] SOMOSKOVI A, SALFINGER M.et al.How Can the Tuberculosis Laboratory Aid in the Patient-Centered Diagnosis and Management of Tuberculosis?[J]. Clin Chest Med, 2019, 40(4): 741-753.
[7] 付寒, 王鹏, 张宗华, 等. 标准抗结核治疗方案对耐多药肺结核患者肾功能的影响分析[J/CD]. 新发传染病电子杂志, 2022, 7(3): 32-36.
[8] WANG N, SHEWADE HD, THEKKUR P, et al.Electronic medication monitor for people with tuberculosis: Implementation experience from thirty counties in China[J]. PLoS One. 2020, 15(4): e0232337.
[9] THU NQ, TIEN NTN, YEN NTH, et al.Push forward LC-MS-based therapeutic drug monitoring and pharmacometabolomics for anti-tuberculosis precision dosing and comprehensive clinical management[J]. J Pharm Anal. 2023, 14(1): 16-38.
[10] 尹洪云, 马俊, 何娅, 等. 小儿抗结核药物治疗255例不良反应临床分析[J]. 中国实用儿科杂志, 2014, 29(4):277-281.
[11] 中华人民共和国国家卫生和计划生育委员会. 肺结核诊断标准(WS 288-2017)[J/CD]. 新发传染病电子杂志, 2018, 3(1):59-61.
[12] 中华医学会结核病学分会.结核分枝杆菌γ-干扰素释放试验及临床应用专家意见(2021年版)[J].中华结核和呼吸杂志, 2022, 45(2):143-150.
[13] DUDNYK A, LUTCHMUN W, DUARTE R, et al.The importance of getting the dose right in the treatment of tuberculosis[J]. Breathe, 2025, 21(1): 240177.
[14] SWAMINATHAN S, PASIPANODYA JG, RAMACHANDRAN G, et al.Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests[J]. Clin Infect Dis, 2016, 63(suppl 3): S63-S74.
[15] LOPEZ-VARELA E, ABULFATHI AA, STRYDOM N, et al.Drug concentration at the site of disease in children with pulmonary tuberculosis[J]. J Antimicrob Chemother. 2022, 77(6): 1710-1719.
[16] LIU W, XU N, LI W, et al.Pharmacokinetics and safety of rifapentine in children: dosing for latent tuberculosis infection. J Antimicrob Chemother[J]. 2025, 80(4): 1022-1030.
[17] 柯涛, 何田, 张培泽, 等. 用二维液相色谱法检测人血清中利福喷丁的浓度[J].中国临床药理学杂志, 2024, 40(11):1638-1641.
[18] 常咏春, 盛莉. 生理药动学模型在特殊人群药物相互作用研究中的应用进展[J]. 中国药理学与毒理学杂志, 2024, 38(11):872-879.
[19] 雷倩, 赵嫄, 王皓, 等. 3种二线抗结核药物血药浓度测定及其影响因素[J].药物分析杂志, 2020, 40(8):1405-1412.
[20] JANSSEN S, VONGJARUDECH T, KARLSSON MO, et al.Bridging to Paediatric Dosing: Relative Bioavailability of Suspended Rifapentine and Isoniazid in an Open-Label Randomized Trial in Adults on Tuberculosis Preventive Therapy[J].Clin Pharmacokinet. 2025, 64(12): 1885-1896.